Efficacy and Tolerability of Weekly Bortezomib, Lenalidomide, and Dexamethasone Protocols in Transplant‐Ineligible Newly Diagnosed Myeloma: An Australian Real‐World, Multicenter Study
This study demonstrates that real-world outcomes of weekly RVD regimens have comparable efficacy to published twice-weekly regimens; however, toxicity remains a significant challenge in this patient population.
Authors
- Giselle Kidson‐Gerber (ORCID: https://orcid.org/0000-0001-5834-0890)
- Silvia Ling (ORCID: https://orcid.org/0000-0001-9739-7101)
- Annmarie Bosco
- Georgia J. B. McCaughan (ORCID: https://orcid.org/0000-0002-4838-9022)
- Angela Hwang (ORCID: https://orcid.org/0000-0001-7937-3333)
- Christian Bryant (ORCID: https://orcid.org/0000-0001-9999-6968)
- F. Kwok
- Jennifer Zhang (ORCID: https://orcid.org/0000-0002-9036-0477)
- Gurdeep Parmar
- Nicole Wong Doo
- Nada Hamad
- P. Joy Ho
- Adam Bryant
- Kristina Whelan
- Samantha Kurniawan
- Parisa Fani‐Molky
- Sam Lai
- Tracy King
Institutions
- The University of Sydney (AU)
- Royal Prince Alfred Hospital (AU)
- Concord Repatriation General Hospital (AU)
- Liverpool Hospital (AU)
- Wollongong Hospital (AU)
- Westmead Hospital (AU)
- UNSW Sydney (AU)
- St Vincent's Hospital Sydney (AU)
- Prince of Wales Hospital (AU)
- St Vincent's Clinic (AU)
Publication Details
- Journal
- Asia-Pacific Journal of Clinical Oncology
- Published
- 2026-03-22
- DOI
- https://doi.org/10.1111/ajco.70101
- Primary Topic
- Multiple Myeloma Research and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00